All In Biotech

Drug Trial Radar · NCT03779074

Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies

Efficacies of Hybrid, High-dose Dual and Bismuth Quadruple Therapies for the First-line Anti-H Pylori Treatment and Tetracycline-levofloxacin Quadruple Therapy for the Second-line Anti-H Pylori Treatment - a Multicentre Randomized Trial

Last checked: Nov 20, 2026Latest source record: Oct 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 918 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

918

Actual

Start

Sep 3, 2018

Primary completion

Dec 31, 2021

Study completion Dec 31, 2021

Sponsor

Lead sponsor
Kaohsiung Veterans General Hospital.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Both hybrid and high-dose dual therapies developed by the scholars from Taiwan can achieve a high eradication rate for clarithromycin-resistant strains, and have a great potential to replace bismuth quadruple therapy in the treatment of H. pylori infection.

Conditions

  • Helicobacter Pylori Infection

Interventions

  • 10d bismuth quadruple therapyDrug

    rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days

  • 14d hybrid therapyDrug

    a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days

  • 14D high-dose dual therapyDrug

    rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants in Which H. Pylori Was EradicatedTime frame: sixth week after the end of anti- H. pylori therapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.